ONS Connect - October 2008 - (Page 30)

Celebrating Commitment to Care in HER2+ Breast Cancer Susan Gardner Seattle, WA West honoree Tara Gehring Chicago, IL Central honoree Nancy Sokolowski Norwalk, CT Northeast honoree Suzanne Perez Houston, TX South honoree Celebrating nurse-patient partnerships in HER2+ breast cancer HER All for Hundreds of nurses across the country were nominated for the All for HER program on the basis of their outstanding work with patients with HER2+ breast cancer. The 4 honorees were chosen for their exemplary ability to support and motivate their patients throughout the course of treatment. On behalf of your patients and their loved ones, thank you for all of your hard work! To learn more about how these nurses have gone above and beyond for their patients with HER2+ breast cancer, stop by the Genentech booth at the ONS 9th Annual Institutes of Learning. Adjuvant indications Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*) breast cancer: • As part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel • With docetaxel and carboplatin • As a single agent following multi-modality anthracycline-based therapy Metastatic indications Herceptin is indicated: • In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer • As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease *High-risk features for patients with ER/PR+ breast cancer include: tumor size >2 cm, age <35 years, and histologic and/or nuclear grade 2/3. Boxed WARNINGS and Additional Important Safety Information Herceptin administration can result in sub-clinical and clinical cardiac failure manifesting as congestive heart failure and decreased left ventricular ejection fraction. Serious infusion reactions and pulmonary toxicity have occurred; fatal infusion reactions have been reported. Exacerbation of chemotherapy-induced neutropenia has also occurred. The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia. Please see next page for Brief Summary of full Prescribing Information, including Boxed WARNINGS and additional important safety information. www.herceptin.com ©2008 Genentech USA So. San Francisco, CA All rights reserved. 9376500 8/08 http://www.herceptin.com http://www.herceptin.com

Table of Contents Feed for the Digital Edition of ONS Connect - October 2008

ONS Connect- October 2008 Contents Editor's Note Just In Up Front You Tell Us Up Close &�Professional Web Connect Five-Minute In-Service Capitol Connection Caregiver Care Straight Talk New Treatments, New Hope Working for You Calendar of Events Staying on Top

ONS Connect - October 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.